Research programme: Nav1.7 voltage-gated sodium channel inhibitors - SiteOne Therapeutics

Drug Profile

Research programme: Nav1.7 voltage-gated sodium channel inhibitors - SiteOne Therapeutics

Alternative Names: GTX analogues - SiteOne Therapeutics; Guanidinium toxin analogues - SiteOne Therapeutics; NaV1.7 inhibitors - OneSite Therapeutics; Sodium ion channel 1.7 inhibitors - OneSite Therapeutics

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Stanford University
  • Developer SiteOne Therapeutics
  • Class Imaging agents; Small molecules
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Muscle hypertonia; Pain; Pruritus

Most Recent Events

  • 06 Jan 2017 SiteOne Therapeutics and Amgen agree to develop NaV1.7 voltage-gated sodium channel inhibitors for Pain
  • 23 Sep 2014 Early research in Hypertonia in USA (PO)
  • 23 Sep 2014 Early research in Cancer (Diagnosis) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top